公开(公告)号：US20240083905A1

公开(公告)日：2024-03-14

申请号：US18363933

申请日：2023-08-02

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade - Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61P25/22

CPC classification number: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20240279232A1

公开(公告)日：2024-08-22

申请号：US18567191

申请日：2021-06-07

Applicant: UWM Research Foundation, Inc.

Inventor： Alexander E. Arnold ,  Douglas C. Stafford ,  James M. Cook ,  Amanda N. Nieman ,  Michael Ming-Jin Poe ,  Guanguan Li

IPC: C07D487/04 ,  A61K31/5517 ,  A61P29/00

CPC classification number: C07D487/04 ,  A61K31/5517 ,  A61P29/00

Abstract: Substituted 5-(4-methyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1.4]diazepin-3-yl)-1.2.4-oxadiazole compounds are ligands for the k opioid receptor and inhibit inducible nitric oxide synthase. The compounds have utility to inhibit NO production and treat associated inflammatory conditions.

公开(公告)号：US20200181146A1

公开(公告)日：2020-06-11

申请号：US16086053

申请日：2017-03-20

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade - Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US09597342B2

公开(公告)日：2017-03-21

申请号：US14637334

申请日：2015-03-03

Applicant: UWM Research Foundation, Inc.

Inventor： James M. Cook ,  Terry S. Clayton ,  Hiteshkumar D. Jain ,  Yun Teng Johnson ,  Jie Yang ,  Sundari K. Rallipalli ,  Zhi-jian Wang ,  Ojas A. Namjoshi ,  Michael Ming-Jin Poe

IPC: A61K31/551 ,  C07D487/04 ,  A61K31/695 ,  C07D487/14 ,  C07D519/00

CPC classification number: A61K31/695 ,  A61K31/551 ,  C07D487/04 ,  C07D487/14 ,  C07D519/00

Abstract: Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

公开(公告)号：US11753412B2

公开(公告)日：2023-09-12

申请号：US17122745

申请日：2020-12-15

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade—Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61K31/5517 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28

CPC classification number: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20210309662A1

公开(公告)日：2021-10-07

申请号：US17122745

申请日：2020-12-15

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade - Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US20190300534A1

公开(公告)日：2019-10-03

申请号：US16283926

申请日：2019-02-25

Applicant: UWM Research Foundation, Inc.

Inventor： James M. Cook ,  Michael Ming-Jin Poe ,  Kashi Reddy Methuku ,  Guanguan Li

IPC: C07D487/04

Abstract: Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

公开(公告)号：US12180216B2

公开(公告)日：2024-12-31

申请号：US18363933

申请日：2023-08-02

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade—Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: C07D487/04 ,  A61K31/551 ,  A61P25/00 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US10906909B2

公开(公告)日：2021-02-02

申请号：US16086053

申请日：2017-03-20

Applicant: UWM Research Foundation, Inc. ,  Centre for Addiction and Mental Health ,  University of Belgrade—Faculty of Pharmacy

Inventor： James M. Cook ,  Guanguan Li ,  Michael Ming-Jin Poe ,  Miroslav M. Savic ,  Etienne Sibille

IPC: A61K31/5517 ,  A61P25/00 ,  C07D487/04 ,  A61P25/22

Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

公开(公告)号：US10259815B2

公开(公告)日：2019-04-16

申请号：US15560002

申请日：2016-03-18

Applicant: UWM Research Foundation, Inc.

Inventor： James Cook ,  Michael Ming-Jin Poe ,  Kashi Reddy Methuku ,  Guanguan Li

IPC: A61K31/5517 ,  A61P25/18 ,  C07D487/04

Abstract: Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.